Blog

Guru Sonpavde: Phase I clinical trial early drug development update from AdventHealth Central Florida

Photo taken from Guru Sonpavde/LinkedIn

Mar 6, 2024, 10:51

Guru Sonpavde: Phase I clinical trial early drug development update from AdventHealth Central Florida

Guru Sonpavde, Medical Director at the AdventHealth Cancer Institute, shared a post on LinkedIn:

“Phase I clinical trial early drug development update from AdventHealth Central Florida cancer institute, Orlando/Celebration Florida -Our rapidly growing Phase I Clinical Research Unit offers new cutting edge cancer therapies to the highly diverse and expanding community of central Florida-Delighted to offer several promising novel agents immunotherapy targeted therapy antibody drug conjugates to treat advanced cancer including the following clinical trials and many more in our constantly growing pipeline: 1) TAC-001 Tallac Therapeutics: CD22 binding antibody drug immune-conjugate that delivers TLR9, 2) STAR-0602 Marengo Therapeutics: bifunctional antibody binding Vβ6/Vβ10 T cell receptors fused to IL-2 to promote activation & expansion of T cells, 3) IMP1734 Eikon Therapeutics Therapeutics: selective PARP1 inhibitor that may offer a better therapeutic index than currently used PARP inhibitors for tumors with DNA repair genomic alterations, 4) KO-2806 Kura Oncology, Inc. Oncology, Inc.: next-generation farnesyl transferase inhibitor to treat advanced malignancies with RAS alterations, 5) SRK181 Scholar Rock: monoclonal antibody to inhibit latent TGFβ1 & potentially overcome PD1 inhibitor resistance, 6) LOXO-435 Loxo Lilly: FGFR3-specific inhibitor with preserved potency against FGFR3 gatekeeper resistance mutants (enrolling FGFR3 mutations, fusions and amplification, and FGF ligand amplifications), 7) CDX585 Celldex Therapeutics: Bispecific antibody that inhibits PD-1 and anti-ILT4 to block immunosuppressive signals in T cells and myeloid cells, 8) MT6402 Molecular Templates: ETB (engineered Toxin Body) that binds PD-L1 and delivers shiga-like toxin and CMV antigen seeding, 9) SGN-B7H4V Seagen Pfizer: Antibody drug conjugate targeting B7H4, 10) PRT3789 Prelude Therapeutics: SMARCA2 degrader PROTAC for SMARCA4 altered tumors. Looking forward to our growing collaborations to offer new therapies to our diverse and growing community in central Florida and beyond- please contact us for more information or to participate – clinical trial participation is critically important to make advances!”

Source: Guru Sonpavde/LinkedIn